Effects of Bispecific Antibodies on Lymphocyte Interactions
Author Information
Author(s): Molema G, Tervaert J W Cohen, Kroesen B J, Helfrich W, Meijer D K F, Leij L F M H de
Primary Institution: Groningen University Institute for Drug Exploration (GUIDE)
Hypothesis
Can bispecific antibodies enhance lymphocyte interactions with endothelial cells?
Conclusion
The bispecific antibody BIS-1 increases lymphocyte adhesion to endothelial cells but does not lead to anti-tumor effects.
Supporting Evidence
- BIS-1 F(ab′)2 caused immunomodulation in carcinoma patients.
- Lymphocyte adhesion to endothelial cells increased when preincubated with BIS-1 F(ab′)2.
- No lymphocyte accumulation in tumor tissue was observed.
Takeaway
This study shows that a special type of antibody can help white blood cells stick to blood vessel walls, but it doesn't help them fight tumors.
Methodology
The study examined the effects of BIS-1 F(ab′)2 on peripheral blood mononuclear cells and their interactions with endothelial cells in vitro.
Limitations
No anti-tumor effect was observed despite increased lymphocyte adhesion.
Participant Demographics
Carcinoma patients in a phase I/II clinical trial.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website